Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2016 07:00 ET | Source: Merus N.V.

Merus Announces First Quarter 2016 Financial Results and Highlights Recent Clinical Progress and Corporate Developments

Raises $53.3 Million in Successful Initial Public Offering Doses First Patient in Phase 1/2 Study of MCLA-117 in Patients with AML UTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) --...
June 01, 2016 07:00 ET | Source: Merus N.V.

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

BERLIN & UTRECHT, The Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial...
May 31, 2016 07:00 ET | Source: Merus N.V.

Merus N.V. Announces Closing of Partial Exercise of Underwriters' Over-Allotment Option

UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today...
May 24, 2016 14:16 ET | Source: Merus N.V.

Merus N.V. Announces Closing of Initial Public Offering

UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial...
May 18, 2016 20:49 ET | Source: Merus N.V.

Merus Announces Pricing of Initial Public Offering

UTRECHT, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering...
May 04, 2016 07:00 ET | Source: Merus N.V.

Merus Announces First Patient Dosed in Phase 1/2 Trial Evaluating Bispecific Antibody Candidate MCLA-117 in Patients with AML

UTRECHT, The Netherlands, May 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first...
April 15, 2016 17:05 ET | Source: Merus N.V.

Merus to Present Interim Clinical Data from Ongoing Phase 1/2 Clinical Trial of its Lead Bispecific Antibody Candidate, MCLA-128, at the American Association for Cancer Research 2016 Annual Meeting

UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics), today...
March 09, 2016 09:00 ET | Source: Merus N.V.

Merus Announces Issuance of Three U.S. Patents Strengthening Its Biclonics® Technology Platform for the Discovery and Manufacturing of Human Bispecific Antibodies

UTRECHT, The Netherlands, March 09, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the...
January 04, 2016 07:00 ET | Source: Merus N.V.

Merus and Gustave Roussy Form Strategic Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Immuno-Oncology Applications

UTRECHT, The Netherlands and VILLEJUIF, France, Jan. 04, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and...
December 16, 2015 07:00 ET | Source: Merus N.V.

Merus Appoints Hui Liu as Chief Business Officer

Novartis Oncology’s Former Global Head of Business Development and Licensing Joins Immuno-oncology Biotech Company UTRECHT, The Netherlands, Dec. 16, 2015 (GLOBE NEWSWIRE) -- Merus B.V., a...